Eqitx appoints chief executive officer

By Renate Krelle
Wednesday, 01 September, 2004

Melbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.

“Sue’s experience in new product development and commercialisation at a number of large pharmaceutical companies including Schering-Plough and Bristol-Myers Squibb, together with her biotechnology industry experience at Agenix and Amgen, have given her an ideal mix of skills to progress the development of our VacTX novel vaccine and ZingoTX Gingerol projects,” said Eqitx Chairman Mr Sol Majteles in a statement. Parry-Jones was most recently vice president of Molecular Diagnostic Imaging at Agenix.

Content from other channels on our network

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Five trends tracked for NZ's fresh produce sector

Poultry and egg producers in lockdown as avian flu detected in WA

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens

Accenture acquires Dragos and increases OT cybersecurity offering

GWW to provide recycled water for a Victorian data centre

Valves, data centres and the invisible infrastructure of Australian industry

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Partnership to develop lower-emission titanium production

Refinery transforms CO2 into useable raw materials

Siemens expands Fusesaver manufacturing facility

Eqitx appoints chief executive officer

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network